Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 12-Week, Phase 2A, Randomized, Subject And Investigator Blinded, Placebo-Controlled Trial To Evaluate The Safety, Tolerability And Efficacy Of CE-326,597 On Glucose Control And Body Weight In Overweight Adult Subjects With Type 2 Diabetes Mellitus

NCT00542009 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT00542009
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00542009 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 12-Week, Phase 2A, Randomized, Subject And Investigator Blinded, Placebo-Controlled Trial To Evaluate The Safety, Tolerability And Efficacy Of CE-326,597 On Glucose Control And Body Weight In Overweight Adult Subjects With Type 2 Diabetes Mellitus
Lead sponsor
Pfizer
Phase
Phase 2
Overall status
Completed
Start date
December 31, 2007
Completion date
November 30, 2008
Enrollment
252 (actual)
Sites
54

Conditions

As the registry lists them; a condition with its own page is linked.

treatment of obesity, weight management